Overview

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and tolerability of AZD2014 when given in combination with Fulvestrant.
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Estradiol
Estrogens
Fulvestrant